CeriBell (NASDAQ:CBLL) Price Target Lowered to $20.00 at TD Cowen

CeriBell (NASDAQ:CBLL) had its price objective cut by TD Cowen from $36.00 to $20.00 in a report released on Wednesday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other brokerages also recently issued reports on CBLL. Weiss Ratings reissued a “sell (e+)” rating on shares of CeriBell in a research report on Wednesday, October 8th. Raymond James Financial assumed coverage on shares of CeriBell in a research report on Tuesday, October 21st. They set a “strong-buy” rating and a $19.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $25.17.

CeriBell Stock Up 7.9%

Shares of NASDAQ:CBLL opened at $11.78 on Wednesday. The company has a market capitalization of $431.90 million and a PE ratio of -7.80. The company has a current ratio of 13.31, a quick ratio of 12.91 and a debt-to-equity ratio of 0.11. CeriBell has a twelve month low of $10.01 and a twelve month high of $32.75. The firm has a 50 day simple moving average of $12.07 and a 200-day simple moving average of $14.60.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings data on Tuesday, November 4th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.43) by $0.06. CeriBell had a negative net margin of 63.35% and a negative return on equity of 28.92%. The company had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell has set its FY 2025 guidance at EPS. On average, equities analysts predict that CeriBell will post -2.46 EPS for the current fiscal year.

Insider Activity

In other news, CTO Raymond Woo sold 11,112 shares of the stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $12.54, for a total value of $139,344.48. Following the completion of the transaction, the chief technology officer owned 167,704 shares in the company, valued at $2,103,008.16. This trade represents a 6.21% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 20.10% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On CeriBell

Large investors have recently made changes to their positions in the stock. KLP Kapitalforvaltning AS purchased a new position in shares of CeriBell in the 1st quarter valued at about $36,000. Tower Research Capital LLC TRC increased its holdings in shares of CeriBell by 353.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock valued at $43,000 after purchasing an additional 1,801 shares in the last quarter. Ameritas Investment Partners Inc. increased its holdings in shares of CeriBell by 97.5% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 2,544 shares of the company’s stock valued at $48,000 after purchasing an additional 1,256 shares in the last quarter. New York State Common Retirement Fund purchased a new position in shares of CeriBell in the 1st quarter valued at about $67,000. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in shares of CeriBell by 161.0% in the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 5,677 shares of the company’s stock valued at $106,000 after purchasing an additional 3,502 shares in the last quarter.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.